Cocrystal Pharma posts Phase 1 results for CDI-988, an oral SARS-CoV-2 antiviral candidate
A first-in-human trial testing single- and multiple-ascending doses of CDI-988 in healthy adults has completed, with results posted after nearly three years.
Cocrystal Pharma's update this week centers on a completed Phase 1 study of its investigational antiviral.
- CDI-988 is described as an SARS-CoV-2 3-chymotrypsin-like (3CL) protease inhibitor for oral administration.1 The trial was a two-part study examining safety, tolerability, and pharmacokinetics, with Part 1 using escalating single doses in sequential cohorts and Part 2 enrolling escalating multiple-dose cohorts.1
- The study is listed as completed, with a primary completion date of 2025-05-23 and study completion on 2025-07-23.1 Enrollment reached 94 participants.1 Results were first posted on 2026-08-19.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.